OUTCOMES AT 3 YEARS IN EBV plus EUROPEAN SUBPOPULATIONS FROM BENEFIT AND BENEFIT-EXT

被引：0
|
作者：
Budde, K. [1 ]
Blancho, G. [2 ]
Merville, P. [3 ]
Moal, M. -C. [4 ]
Rostaing, L. [5 ]
Harler, M. B. [6 ]
Grinyo, J. [7 ]
机构：
[1] Charite, D-13353 Berlin, Germany
[2] Univ Hosp Nantes, Nantes, France
[3] CHU Bordeaux, Bordeaux, France
[4] CHU Brest, F-29285 Brest, France
[5] CHU Toulouse, Toulouse, France
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Hosp Univ Bellvitge, Barcelona, Spain
来源：
TRANSPLANT INTERNATIONAL | 2014年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
P030
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [41] Renal Function in Patients Treated with Belatacept- or Cyclosporine-Based Regimens at Year 3 in the BENEFIT and BENEFIT-EXT Studies
    Durrbach, A.
    Citterio, F.
    Mulloy, L.
    David-Neto, E.
    Russ, G.
    Vitko, S.
    Zhang, R.
    Xing, J.
    Harler, M. B.
    Grinyo, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 100 - 100
  • [42] Five-Year Outcomes by Donor Type from the Long-Term Extension of the Belatacept BENEFIT-EXT Study
    Durrbach, A.
    Florman, S.
    Zhang, R.
    Lang, P.
    Lehner, F.
    Massari, P.
    Garcia, V.
    Pupim, L.
    Muehlbacher, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 311 - 311
  • [43] Likelihood of Improving or Sustaining Renal Function Over Three Years with Belatacept or CsA: Insights from the BENEFIT-EXT Study
    Vanrenterghem, Y.
    Medina Pestana, J.
    Becker, T.
    Rial, M.
    Agarwal, M.
    Lin, C-S
    Grinyo, J.
    TRANSPLANTATION, 2012, 94 (10) : 986 - 986
  • [44] Outcomes as a Function of Donor Criteria from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT-EXT).
    Florman, Sander
    Durrbach, Antoine
    Larsen, Christian
    Pestana, Jose Medina
    Vanrenterghem, Yves
    Vincenti, Flavio
    Block, Alan
    Garg, Pushkal
    Copley, J. Brian
    Xing, Jun
    Grinyo, Josep
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 150 - 150
  • [45] Modeled Long Term Projections of Clinical Outcomes from BENEFIT and BENEFIT-EXT.
    Levy, A.
    Johnston, K.
    Kalsekar, A.
    Schnitzler, M.
    L'Italien, G.
    Kasiske, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 406 - 407
  • [46] Mismatched Epitope and De Novo DSA Development: An Analysis of the Benefit and Benefit-EXT Renal Transplant Cohorts.
    Jucaud, V.
    Burnett, V.
    Gebel, H.
    Bray, R.
    Polinsky, M.
    Everly, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 384 - 384
  • [47] Belatacept Pharmacokinetic Analysis Comparing Belatacept Early Steroid Withdrawal Trial (BEST) with Benefit and Benefit-ext Trials
    Bickenbach, A.
    McGowan, M.
    Miyagawa, B.
    Mizuno, T.
    Shields, A.
    Christianson, A.
    West-Thielke, P.
    Leone, J.
    Woodle, E.
    Kaufman, D.
    Wiseman, A.
    Matas, A.
    Vinks, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 364 - 365
  • [48] Four-Year Outcomes in Black/African American Kidney Transplant Recipients from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies.
    Florman, S.
    Rice, K.
    Chan, L.
    Steinberg, S.
    Pearson, T.
    Duan, T.
    Argawal, M.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 404 - 404
  • [49] Primary Outcomes from a Randomized, Phase III Study of Belatacept Versus Cyclosporine in ECD Kidney Transplants (BENEFIT-EXT Study)
    Durrbach, Antoine
    Florman, Sander
    Larsen, Christian
    Pestana, Jose Medina
    Vanrenterghem, Yves
    Vincente, Flavio
    Block, Alan
    Garg, Pushkal
    Grinyo, Josep
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 7 - 7
  • [50] PRIMARY OUTCOMES FROM A RANDOMIZED, PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN ECD KIDNEY TRANSPLANTS (BENEFIT-EXT STUDY)
    Durrbach, A.
    Larsen, C.
    Medina-Pestana, J. D.
    Vanrenterghem, Y.
    Vincenti, F.
    Florman, S.
    Block, A. J.
    Garg, P.
    Sen, K.
    Grinyo, J. M.
    TRANSPLANT INTERNATIONAL, 2009, 22 : 89 - 89
12345